G-CSF

Kathryn Dzintars, Pharm.D., BCPS, Paul A. Pham, Pharm.D.

INDICATIONS

FDA

  • Chemotherapy-induced neutropenia in patients with cancer
  • Neutropenia following bone marrow transplantation
  • Mobilization of hematopoietic progenitor cells for collection by leukopheresis
  • Idiopathic, cyclic or congenital neutropenia
  • Increase survival in patients acutely exposed to myelosuppressive doses of radiation (Hematopoietic Syndrome of Acute Radiation Syndrome)

NON-FDA APPROVED USES

  • Severe neutropenia associated with HIV and/or opportunistic infections
  • Drug-induced neutropenia (AZT, ganciclovir, pyrimethamine, TMP/SMX and others)
  • Prolonged neutropenia/immune effector cell-associated hematologic toxicity (ICAHT) after CAR T-cell therapy (not recommended within 14 days of infusion per NCCN due to theoretical cytokine release syndrome risk).

There's more to see -- the rest of this topic is available only to subscribers.

Last updated: September 10, 2026